Validation of a first‐generation epstein‐barr virus vaccine preparation suitable for human use

Journal of Medical Virology - Tập 29 Số 1 - Trang 74-78 - 1989
Anthony J. Morgan1, A. C. Allison2, S. Finerty3, F. T. Scullion3, Noelene E. Byars2, M. A. Epstein4
1Department of Pathology, University of Bristol Medical School, University Walk, England.
2Department of Immunology, Syntex Research, Palo Alto, CA
3Department of Pathology, University of Bristol Medical School, University Walk, Bristol, England
4Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford England

Tóm tắt

AbstractThe efficacy of a new vaccine preparation against Epstein‐Barr (EB) virus was investigated in cotton‐top tamarins. The vaccine consists of fast protein liquid chromatography‐purified EB virus membrane antigen glycoprotein of 340 Kd (MA gp340) mixed with a synthetic muramyl dipeptide adjuvant emulsified in squalane containing a pluronic polymer; it is suitable for both scaled‐up batch production and eventual administration to man. Vaccinated tamarins rapidly developed ELISA detectable high titre antibodies to MA gp340, and their sera became strongly EB virus‐neutralising. After challenge with a massive 100% carcinogenic dose of EB virus, the vaccinated tamarins had a strikingly low level of circulating EB virus‐carrying mononuclear cells, in contrast to a control animal, and remained entirely free of tumours. This first‐generation vaccine has thus been validated in experimental animals and the way opened for a phase I human trial.

Từ khóa


Tài liệu tham khảo

10.1016/0022-1759(86)90402-3

10.1038/nbt1087-1041

Böyum A, 1968, Separation of leucocytes from blood and bone marrow, Scandinavian Journal of Clinical Laboratory Investigations [Supple 97], 21, 77

Burkitt D, 1963, International Review of Experimental Pathology, 67

10.1126/science.2986287

10.1016/0022-1759(88)90424-3

10.1002/ijc.2910130311

10.1093/jnci/56.4.697

10.1098/rspb.1984.0019

10.1016/S0140-6736(86)91565-5

Epstein MA, 1983, Clinical consequences of Epstein‐Barr virus infection and possible control by an antiviral vaccine, Clinical and Experimental Immunology, 53, 257

10.1038/318287a0

Epstein MA, 1986, Not all potently neutralizing, vaccine‐induced antibodies to Epstein‐Barr virus ensure protection of susceptible experimental animals, Clinical and Experimental Immunology, 63, 485

Henle G, 1966, Immunofluorescence in cells derived from Burkitts lymphoma, Journal of Bacteriology, 91, 1248, 10.1128/jb.91.3.1248-1256.1966

10.1099/0022-1317-25-1-1

10.1258/002367783781070867

10.1258/002367785780887491

10.1002/ijc.2910160117

10.1084/jem.145.4.948

10.1016/0167-5699(87)90008-9

10.1038/308457a0

10.1099/0022-1317-69-8-2093

10.1099/0022-1317-17-2-233

10.1016/0166-0934(84)90026-0

10.1002/ijc.2910190606

Shanmugaratnam K, 1971, International Review of Experimental Pathology, 361

10.1016/0272-0590(88)90288-6

10.1002/ijc.2910350107

Thông tin
Thông tin xuất bản

Journal of Medical Virology

Tập 29 Số 1

74-78

Thông tin tác giả